Top-20 cancer therapy brands market report from C&M

Companies and Markets has announced the addition of Commercial Insight - Top 20 Therapy Cancer Brands market research report to its portfolio. The report shows that cancer therapy brand sales totalled over $30.0 billion in the seven major markets in 2007, growing by 20.1% since 2006. The high growth of this sector makes it attractive to companies keen to emulate the blockbuster status achieved by several brands. However, with several impending patent expires due, drugmakers will need to work hard to maximize their return throughout the lifecycle of their brands.

The top 20 cancer drug brands in the seven major markets contributed the majority ($26.1 billion, 85%) of sector sales in 2007. It is forecast that the total market will grow to $62.4 billion by 2017 at a compound annual growth rate of 7%. The leading 20 in 2017 will still contribute a high proportion of this (80%) with revenue reaching $50.2 billion. Targeted therapies will increasingly dominate the top 20 cancer brands leaderboard, accounting for 12 of the 20 names in the seven major markets in 2017. Avastin (bevacizumab) is forecast to become the leading cancer therapy, facilitated by further indication expansion and high physician familiarity.